Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
Wolfram Pönisch, Paris S. Mitrou(Goethe University Frankfurt), K Merkle, Michael Herold(Helios Klinikum Erfurt), Michael Aßmann, G. Wilhelm(Harz University of Applied Sciences), Klaus Dachselt(Südharz Klinikum), Peter C. Richter, Veronika Schirmer(Vogtland-Klinik), Antina Schulze(Helios Klinikum Erfurt), R. Šubert(Helios Hospital Schwerin), B. Harksel, Norbert Grobe(Klinikum Brandenburg), Ernst H. K. Stelzer(SRH Wald-Klinikum Gera), Maximilian Schulze, A. Bittrich, Mathias Freund(University of Rostock), R. Pasold(Klinikum Ernst von Bergmann), Th. Friedrich, W Helbig(Leipzig University), Dietger Niederwieser(Leipzig University)
Cited by 191Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis